The study enrolled 296 men with suspected prostate cancer, and the results indicated that the combination of mpMRI and PSMA PET/CT reduced false negatives for csPCa compared with MRI alone, potentially allowing a reduction in the number of prostate biopsies required to diagnose csPCa [91]. The gene discussed is FOLH1; the disease is prostate carcinoma.